Cambridge Cog Regulatory News (COG)

8 December 2015

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

New medical device will assess cognitive health and wellbeing

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in digital neuropsychological tests including those enabling the early detection of dementia, announces the launch of CANTAB Insight, a new ground-breaking medical application which rapidly assesses an individual's cognitive health and wellbeing faster access to the most appropriate treatments and care.

With 1 in 4 adults experiencing a diagnosable mental health problem each year1 and the annual cost now exceeding $2.5 trillion2 globally, there is a great need for expert cognitive measures to help identify and triage patients for early intervention and treatment.

Over 25,000 patient evaluations have now been carried out in the UK with the Alzheimer's triage tool CANTAB Mobile. To support this successful introduction, the Company has developed CANTAB Insight for practitioners to perform further in-depth neuropsychological evaluations with at risk patients on an iPad in just 20 minutes.

CANTAB Mobile identifies the initial signs of clinically relevant memory problems and now CANTAB Insight will allow in-depth evaluation with at risk patients to detect underlying signs of common mental health problems such as depression, schizophrenia and dementia at a very early stage.

CANTAB Insight's new touchscreen assessment has now gained CE marking approval for use as a Class II medical device and it will now be licensed into European public and occupational health markets through corporate partnerships as part of the Company's ongoing strategy to provide leading neurotechnology products for healthcare services and pharmaceutical developers worldwide.

Director of Healthcare Innovation at Cambridge Cognition, Dr Jenny Barnett commented: "CANTAB Insight will empower users to accurately triage individuals, recommend efficacious interventions and promote better lifestyle management to improve cognitive health and wellbeing - leading to better outcomes for patients and their families."

Chief Operating Officer, Dr Steven Powell added: "With CANTAB Insight now providing full cognitive health assessments alongside CANTAB Mobile, our healthcare technology business is in a strong position for geographic expansion in 2016."

For further information visit www.CANTAB.com/insight 

1 The Office for National Statistics Psychiatric Morbidity report, 2001.

2 World Health Organization. Global status report on non-communicable diseases, 2010.

Enquiries:

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touchscreen CANTAB™ neuropsychological tests, highly validated by over 1,600 peer-reviewed publications, are used by both academic scientists in their research to maximise knowledge of cognitive function, and clinical researchers in the pharmaceutical industry to develop safe and effective treatments for cognitive disorders. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products to improve the monitoring, management and maintenance of cognitive health and wellbeing.